Dasatinib is a second-generation BCR-ABL/Src kinase inhibitor with activity against most imatinib-resistant BCR-ABL mutations except T315I, used for chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia. Simson Pharma's Dasatinib reference standard and impurities support stability-indicating method development for this targeted leukaemia therapy.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Dasatinib Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.